JP2001510826A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001510826A5 JP2001510826A5 JP2000504111A JP2000504111A JP2001510826A5 JP 2001510826 A5 JP2001510826 A5 JP 2001510826A5 JP 2000504111 A JP2000504111 A JP 2000504111A JP 2000504111 A JP2000504111 A JP 2000504111A JP 2001510826 A5 JP2001510826 A5 JP 2001510826A5
- Authority
- JP
- Japan
- Prior art keywords
- auxiliaries
- active
- compounds according
- active compound
- art
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 5
- 238000000034 method Methods 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- -1 patches Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Description
更に、本発明は、上記の疾病の１つを罹患しているヒトを含む哺乳動物の治療方法に関する。本方法は、治療学的に活性で、薬理学的に有効で、かつ許容できる量の本発明による１つまたはそれ以上の化合物が病気の哺乳動物に投与されることにより特徴付けられる。
医薬品は、当業者に公知の方法で製造される。薬剤として、本発明による化合物（＝活性化合物）は、それ自体、または適した薬剤学的助剤と組み合わせて、例えば錠剤、コーチング錠、カプセル剤、坐剤、パッチ、乳剤、懸濁剤、ゲルまたは溶液の形で使用され、その際、活性化合物含量は、有利に０．１〜９５％である。
当業者は、専門知識に基づいて好ましい医薬配合物に適した助剤を熟知している。溶剤に加えて、ゲル形成剤、軟膏基剤および他の活性化合物助剤、たとえば抗酸化剤、分散剤、乳化剤、保存剤、可溶化剤または浸透促進剤を使用することができる。
当業者は、専門知識に基づいて好ましい医薬配合物に適した助剤を熟知している。溶剤に加えて、ゲル形成剤、軟膏基剤および他の活性化合物助剤、たとえば抗酸化剤、分散剤、乳化剤、保存剤、可溶化剤または浸透促進剤を使用することができる。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97112794 | 1997-07-25 | ||
| EP97112794.9 | 1997-07-25 | ||
| PCT/EP1998/004476 WO1999005112A1 (en) | 1997-07-25 | 1998-07-18 | Substituted 6-alkylphenanthridines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001510826A JP2001510826A (ja) | 2001-08-07 |
| JP2001510826A5 true JP2001510826A5 (ja) | 2006-01-05 |
Family
ID=8227118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000504111A Withdrawn JP2001510826A (ja) | 1997-07-25 | 1998-07-18 | 置換６−アルキルフェナントリジン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6214839B1 (ja) |
| EP (1) | EP1000034B1 (ja) |
| JP (1) | JP2001510826A (ja) |
| AT (1) | ATE224372T1 (ja) |
| AU (1) | AU9066498A (ja) |
| DE (1) | DE69808099T2 (ja) |
| DK (1) | DK1000034T3 (ja) |
| ES (1) | ES2184318T3 (ja) |
| PT (1) | PT1000034E (ja) |
| SI (1) | SI1000034T1 (ja) |
| WO (1) | WO1999005112A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2715683A1 (en) | 1999-08-21 | 2001-03-01 | Nycomed Gmbh | Synergistic combination |
| WO2002005616A1 (en) * | 2000-07-14 | 2002-01-24 | Altana Pharma Ag | Novel 6-phenylphenanthridines |
| ES2236288T3 (es) | 2000-07-14 | 2005-07-16 | Altana Pharma Ag | 6-heteroarilfenantridinas. |
| ATE353217T1 (de) * | 2002-08-29 | 2007-02-15 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
| DE60310576T2 (de) | 2002-08-29 | 2007-10-31 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer |
| EP1720835B1 (en) | 2004-02-18 | 2012-12-12 | Nycomed GmbH | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors |
| AR049419A1 (es) * | 2004-03-03 | 2006-08-02 | Altana Pharma Ag | Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo |
| CN104817534A (zh) | 2004-03-03 | 2015-08-05 | 塔科达有限责任公司 | 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途 |
| MXPA06009892A (es) * | 2004-03-10 | 2007-03-01 | Altana Pharma Ag | Nuevas hidroxi-6-fenilfenantridinas sustituidas con amido y su uso como inhibidores de la fosfodiesterasa tipo 4 (pde4). |
| CA2577108A1 (en) | 2004-08-31 | 2006-03-09 | C.R. Bard, Inc. | Self-sealing ptfe graft with kink resistance |
| NZ560268A (en) | 2005-03-02 | 2010-12-24 | Nycomed Gmbh | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
| EP1887968A4 (en) * | 2005-06-08 | 2013-01-23 | Bard Inc C R | TRANSPLANTS AND STENTS WITH INORGANIC BIOKOMPATIBLE CALCIUM SALT |
| EP1890641B1 (en) | 2005-06-17 | 2017-04-19 | C.R. Bard, Inc. | Vascular graft with kink resistance after clamping |
| WO2007056761A2 (en) | 2005-11-09 | 2007-05-18 | C.R. Bard Inc. | Grafts and stent grafts having a radiopaque marker |
| EP2079575B1 (en) | 2006-10-12 | 2021-06-02 | C.R. Bard, Inc. | Methods for making vascular grafts with multiple channels |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1199773B (de) * | 1962-02-23 | 1965-09-02 | Hoffmann La Roche | Verfahren zur Herstellung von 6-Methyl-8, 9-methylendioxy-1, 2, 3, 4, 4a, 5, 6, 10b-octahydrophenanthridin und dessen Salzen |
| US3243438A (en) | 1962-02-23 | 1966-03-29 | Hoffmann La Roche | Octahydro phenanthridine compounds |
| US4309545A (en) * | 1980-07-28 | 1982-01-05 | Pfizer Inc. | Oximino-1-hydroxyoctahydrobenzo[c]quinolines and derivatives thereof |
-
1998
- 1998-07-18 EP EP98942571A patent/EP1000034B1/en not_active Expired - Lifetime
- 1998-07-18 ES ES98942571T patent/ES2184318T3/es not_active Expired - Lifetime
- 1998-07-18 DK DK98942571T patent/DK1000034T3/da active
- 1998-07-18 WO PCT/EP1998/004476 patent/WO1999005112A1/en active IP Right Grant
- 1998-07-18 PT PT98942571T patent/PT1000034E/pt unknown
- 1998-07-18 JP JP2000504111A patent/JP2001510826A/ja not_active Withdrawn
- 1998-07-18 SI SI9830300T patent/SI1000034T1/xx unknown
- 1998-07-18 AT AT98942571T patent/ATE224372T1/de not_active IP Right Cessation
- 1998-07-18 AU AU90664/98A patent/AU9066498A/en not_active Abandoned
- 1998-07-18 US US09/462,507 patent/US6214839B1/en not_active Expired - Fee Related
- 1998-07-18 DE DE69808099T patent/DE69808099T2/de not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001510826A5 (ja) | ||
| ES2257757T3 (es) | Carboxilato de terfenadina y el tratamiento de trastornos alergicos. | |
| RU2007104095A (ru) | Применение твердой пероральной дозировочной композиции пролонгированного действия для приготовления лекарственных средств | |
| CA2301017A1 (en) | Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds | |
| EE04800B1 (et) | Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks | |
| CA2093806A1 (en) | Method of treating or preventing type 1 diabetes by oral administration of insulin | |
| GEP20002298B (en) | Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment | |
| SE9503924D0 (sv) | Novel opioid peptides | |
| DE60120648D1 (de) | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung | |
| CA2111836A1 (en) | Spin-trapping pharmaceutical compositions and methods for use thereof | |
| CA2219115A1 (en) | N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs | |
| JP2004527551A5 (ja) | ||
| SE9704833D0 (sv) | New formulation | |
| JP2002524415A5 (ja) | ||
| DE69424777D1 (de) | 3,4-diarylchromane zur behandlung von dermatitis | |
| JP2003504332A5 (ja) | ||
| JP2002523437A5 (ja) | ||
| WO2001012214A3 (en) | MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) | |
| RU2001118854A (ru) | Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний | |
| RU97120700A (ru) | Новое фармакологическое применение антагонистов a-ii рецептора | |
| RU2209064C2 (ru) | Новое применение в медицинских целях | |
| CA2091134A1 (en) | Therapeutic agent for threatened abortion | |
| KR890012942A (ko) | 5-치환된 오르니틴 유도체 | |
| JPH08505402A (ja) | 粘膜表皮性及び表皮性の痛み、炎症及び感染症の治療方法及び治療用組成物 | |
| AU2173101A (en) | Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents |